Payment overview · 2025
General Payments
$767.65
8 reported records · 3 companies
Healthcare provider profile · identity verified
John Hanna, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HUDSON, FL · NPI 1548765464
Verified facts
What the public records show
CMS Open Payments records show John Hanna, MD received $767.65 in general payments during 2025 across 8 reported records.
Solventum Corporation accounted for 88.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Solventum Corporation | Unresolved — no canonical attribution shown | $679.10 | 88.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.36 | 9.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.19 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $484.10 | 2 |
| Food and Beverage | $283.55 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| 3M Cavilon Normalized: 3m cavilon |
Device | Solventum Corporation | $679.10 | 4 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $447.13 | 3 | 2025 |
Source payment records
|
|||||
| KerraMax Care Normalized: kerramax care |
Device | Solventum Corporation | $447.13 | 3 | 2025 |
Source payment records
|
|||||
| 3M Coban Normalized: 3m coban |
Device | Solventum Corporation | $120.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 361 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 87 |
| Gabapentin | Gabapentin | 295 | 71 |
| Eliquis | Apixaban | 277 | 71 |
| Furosemide | Furosemide | 243 | 72 |
| Lisinopril | Lisinopril | 178 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 176 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 52 |
| Losartan Potassium | Losartan Potassium | 153 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 44 |
| Trazodone Hcl | Trazodone Hcl | 130 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 109 | 15 |
| Tramadol Hcl | Tramadol Hcl | 108 | 41 |
| Mirtazapine | Mirtazapine | 102 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 33 |
| Potassium Chloride | Potassium Chloride | 92 | 47 |
| Metformin Hcl | Metformin Hcl | 90 | 38 |
| Sertraline Hcl | Sertraline Hcl | 88 | 31 |
| Spironolactone | Spironolactone | 83 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 78 | 32 |
| Carvedilol | Carvedilol | 77 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 22 |
| Donepezil Hcl | Donepezil Hcl | 70 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 29 |
| Levetiracetam | Levetiracetam | 65 | 16 |
| Warfarin Sodium | Warfarin Sodium | 65 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 61 | 21 |
| Montelukast Sodium | Montelukast Sodium | 61 | 19 |
| Glipizide | Glipizide | 60 | 19 |
| Divalproex Sodium | Divalproex Sodium | 52 | 14 |
| Latanoprost | Latanoprost | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Lactulose | Lactulose | 48 | 12 |
| Omeprazole | Omeprazole | 48 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 12 |
| Prednisone | Prednisone | 47 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 29 |
| Memantine Hcl | Memantine Hcl | 46 | 11 |
| Baclofen | Baclofen | 45 | 13 |
| Nystatin | Nystatin | 45 | 18 |
| Alprazolam | Alprazolam | 44 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Cephalexin | Cephalexin | 42 | 21 |
| Levofloxacin | Levofloxacin | 42 | 28 |
| Midodrine Hcl | Midodrine Hcl | 42 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 20 |
| Allopurinol | Allopurinol | 41 | 14 |
| Methylprednisolone | Methylprednisolone | 40 | 32 |
| Simvastatin | Simvastatin | 40 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Meloxicam | Meloxicam | 38 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Famotidine | Famotidine | 36 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 13 |
| Alendronate Sodium | Alendronate Sodium | 33 | 12 |
| Atenolol | Atenolol | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 17 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Meropenem | Meropenem | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 11 |
| Lorazepam | Lorazepam | 29 | 12 |
| Sucralfate | Sucralfate | 28 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | 12 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 12 |
| Fluconazole | Fluconazole | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 12 |
| Fiasp | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Daptomycin | Daptomycin | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $767.65 · 8 records | Solventum Corporation | 3M Cavilon, 3M Coban, ACTIV.A.C., KerraMax Care, QULIPTA, UBRELVY, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error